Protocol  H8H- MC-LAIF(a) A Phase 1, Randomized, Subject - and Investigator -Blink,Placebo -Controlled, 4 -
Period Cross -Over Study Assessing the Duration of Effect of Lasmiditan on Stimulated Driving 
Performance in Healthy Volunteers  
 
[STUDY_ID_REMOVED] 
Approval date: 21 Feb 2018 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 1
LY573144Protocol H8H -MC-LAIF(a)
A Phase I, Randomized, Subject -and Investigator -Blind, 
Placebo- Controlled, 4 -Period Cross- Over Study  Assessing 
the Duration of Effect of Lasmiditan on Simulated Driving 
Performance in Healthy  Volunteers
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
lasmiditan (LY573144) , unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries. 
Lasmiditan (LY573144)
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly :
15 February 2018
Amendm ent (a) Electronically Signed and Approved by Lilly on approval date provided 
below.
Approval Date: 21-Feb-2018 GMT
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 2
LY573144Table of Contents
A Phase I, Randomized, Subject -and Investigator -Blind, 
Placebo- Controlled, 4 -Period Cross- Over Study  Assessing 
the Duration of Effect of Lasmiditan on Simulated Driving 
Performance in Healthy  Volunteers
Section Page
Protocol  H8H -MC-LAIF(a) A Phase I, Randomized, Subject -and 
Invest igator -Blind, Placebo -Controlled, 4- Period Cross -Over Study 
Assessing the Duration of Effect of Lasmiditan on Simulated Driving 
Perform ance in Healt hy Vo lunteers..................................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Schedule of Act ivities....................................................................................................... 12
3. Introduction ...................................................................................................................... 15
3.1. Study  Rati onale ............................................................................................................ 15
3.2. Background .................................................................................................................. 16
3.3. Benefit/Risk Assessment .............................................................................................. 17
4. Object ives and Endpo ints.................................................................................................. 18
5. Study  Design ..................................................................................................................... 20
5.1. Overall Design ............................................................................................................. 20
5.2. Num ber of Participants .................................................................................................20
5.3. End of Study  Definit ion............................................................................................... 20
5.4. Scientific Rationale for Study  Design ........................................................................... 20
5.5. Justification for Dose ................................................................................................... 21
6. Study  Popul ation............................................................................................................... 22
6.1. Inclusio n Cri teria.......................................................................................................... 22
6.2. Exclusio n Cri teria........................................................................................................ 23
6.2.1. Rationale for Excl usion of Certain Study  Candidates ........................................... 26
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 26
6.3.1. Meals and Dietary  Restri ctions............................................................................. 26
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 26
6.3.3. Activity................................................................................................................ 27
6.4. Screen Failures ............................................................................................................. 27
7. Treat ment .......................................................................................................................... 28
7.1. Treatment Administered ............................................................................................... 28
7.1.1. Packaging and Labeling ....................................................................................... 29
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 3
LY5731447.2. Method of Treatment Assignment ................................................................................ 29
7.2.1. Selection and Timing o f Doses ............................................................................. 29
7.3. Blinding ....................................................................................................................... 30
7.4. Dose Modificat ion........................................................................................................ 30
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 30
7.6. Treatment Compliance .................................................................................................31
7.7. Concomitant Therapy ................................................................................................... 31
7.8. Treatment after the End of the Study ............................................................................ 31
8. Discontinuati on Cri teria .................................................................................................... 32
8.1. Discontinuati on from Study  Treatm ent......................................................................... 32
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 32
8.2. Discontinuati on from the Study .................................................................................... 32
8.3. Patients/Subjects Lost to Follow -up.............................................................................. 33
9. Study  Assessments and Procedures ................................................................................... 34
9.1. Efficacy Assessments ................................................................................................... 34
9.2. Adverse Events ............................................................................................................ 34
9.2.1. Serious Adverse Events ........................................................................................ 35
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 35
9.2.2. Com plaint Handling ............................................................................................. 36
9.3. Treatment of Overdose ................................................................................................
.36
9.3.1. Overdose of Lasmiditan ....................................................................................... 36
9.3.2. Overdose of Diphenhydramine ............................................................................. 36
9.4. Safety........................................................................................................................... 36
9.4.1. Laboratory  Tests .................................................................................................. 36
9.4.2. Vital Signs ........................................................................................................... 36
9.4.3. Electrocardi ogram s.............................................................................................. 37
9.4.4. Safety Moni toring ................................................................................................ 37
9.4.4.1. Hepati c Safet y................................................................................................ 38
9.5. Pharmacokinet ics......................................................................................................... 38
9.5.1. Bioanalysis ........................................................................................................... 38
9.6. Pharmacodynamics ...................................................................................................... 39
9.6.1. Country  Vigilance -Divided Attention Driving Scenario on 
the CRCDS -MiniSim ........................................................................................... 39
9.6.2. Karo linska Sleepiness Scale ................................................................................. 39
9.6.3. Self-Perceived Safety  to Drive Quest ion............................................................... 39
9.6.4. CogScreen Symbo l Digit Coding .......................................................................... 39
9.6.5. Visual Anal og Scale to Assess Subject’s Motivat ion and 
Self-Appraisal ...................................................................................................... 40
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 4
LY5731449.7. Genet ics....................................................................................................................... 40
9.8. Heal th Economics ........................................................................................................ 40
10. Statistical Considerations and Data Analysis ..................................................................... 41
10.1. Sample Si ze Determinat ion.......................................................................................... 41
10.2. Popul ations for Analyses .............................................................................................. 41
10.2.1. Study  Parti cipant Disposit ion............................................................................... 41
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 41
10.3. Statistical Analyses ...................................................................................................... 41
10.3.1. Safety Analyses .................................................................................................... 42
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 42
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 42
10.3.2. Pharmacokinet ic Analyses .................................................................................... 42
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 42
10.3.3. Pharmacodynamic Analyses ................................................................................. 42
10.3.3.1. Pharmacodynamic Statistical Inference ........................................................... 43
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 44
11. References ........................................................................................................................ 45
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 5
LY573144List of Tables
Table Page
Table LAIF.1. Object ives and Endpo ints....................................................................... 18
Table LAIF.2. Treatments Administered ........................................................................ 28
Table LAIF.3. Treatment Schedule ................................................................................ 28
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 6
LY573144List of Figures
Figure Page
Figure LAIF.1. Study  schemat ic...................................................................................... 20
Figure LAIF.2 Timing of doses. ..................................................................................... 29
Figure LAIF.3. Pharmacodynamic statist ical inference –graphical mult iple 
comparisons procedure. .......................................................................... 43
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 7
LY573144List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 46
Appendix 2. Clinical Laboratory  Tests ........................................................................ 50
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 51
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 54
Appendix 5. Blood Sam pling Summary ...................................................................... 55
Appendix 6. Protocol  Amendment H8H -MC-LAIF(a) Summary: A P hase I, 
Randomized, Subject -and Invest igator -Blind, Placebo -Controlled, 
4-Period Cross -Over Study Assessing the Duration of Effect of 
Lasmiditan on Simulated Driving Performance in Healthy 
Volunteers .............................................................................................. 56
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 8
LY5731441.Protocol Sy nopsis
Title of Study:
Protocol H8H -MC -LAIF: A Phase I, Randomized, Subject -and Investigator -Blind, Placebo -Controlled, 4-Period 
Cross -Over Study Assessing the Duration of Effect of Lasmiditan on Simulated Driving Performance in Healthy 
Volunteers
Rationale:
Lasmiditan is a highly selective and potent agonist at the 5 -hydroxytryptamine 1Freceptor and is under development 
as a neurally acting acute treatment for migraine.  The most frequently report ed adverse events (AEs) identified in 
the lasmiditan clinical development program are central nervous system in nature based on the mechanism of action 
of the drug .  Due to treatment -related adverse effects of dizz iness and fatigue observed in the Phase 2 clinical 
program, Study COL -MIG -106/ H8H-MC -LAHG evaluated the impact of lasmiditan on driving performance at 90 
minutes postdose.  The results of this study showed impaired driving performance, but the duration of the 
impairment could not be estimated.  The primary objective ofthe current study is to determine the duration of effect 
of lasmiditan compared to placebo on simulated driving performance in healthy subjects as measured by standard 
deviation of lateral position ( SDLP) using the Cognitive Research Corporation Driving Simulator -Min iSim 
(CRCDS -MiniSim) at 8, 12, and 24 hours after dosing.
Objectives Endpoints
Primary
To determine the duration of effect of acute doses of 
lasmiditan 100 mg and 200 mg compared to placebo 
on simulated driving performance in healthy subjectsStandard deviation of lateral position (SDLP) using the 
Cognitive Research Corporation Driving Simulator -
MiniSim (CRCDS -MiniSim) at 8,12, and 24 hours 
postdose
Secondary
To determi ne the effects of lasmiditan 100 mg, and 
200 mg compared to placebo on
self-reported endpoints Sleepiness endpoint -KSS
Self-reported readiness to drive (“Right now do 
you feel safe to drive?)
VAS to assess subject’s motivation and 
self-appraisal of their driving performance
performance endpoints, and CogScreen SDC test
Number of correct responses
Response accuracy
Standard deviation of reaction time
driving performance endpoints . Lane exceedance; including number, maximum, 
duration, and area of exceedance
Average speed, speed deviation, speed count
Excessive Ay (cornering speed threshold 
exceeded)
Total collisions
Divided attention (DA): correct responses, 
omission errors, commission errors, reaction time, 
standard deviation of reaction times
To evaluate the PK of lasmiditan in healthy subjects PK parameters:  
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 9
LY573144following a single 100- or 200 -mg oral dose of 
lasmiditanoCmax, 
otmax, and 
oAUC(0 -∞)
Abbreviations:  AUC(0 -∞)= area under the concentration versus time curve from zero to infinity; Cmax= maximum 
observed drug concentration ;DA = divided attention; KSS = Karolinska Sleepiness Scale ; PK = 
pharmacokinetics; SDC = Symbol Digit Coding ; tmax= time of maximum observed drug concentration; VAS = 
Visual Analog Scale.
Summary of Study Design:
Study H8H-MC -LAIF is a multicenter, randomized, subject -and investigator -blind, active -and placebo -controlled 
Williams square design with 4 -period (full) crossover using lasmiditan 200 mg, lasmiditan 100 mg, and 
diphenhydramine 50 mg. Subjects will be r andomized to treatment sequences and will complete all 4 periods within 
that treatment sequence.
Each period will be of 3 day s duratio n.  It is anticipated that Study Periods 1, 2, 3, and 4 will commence on Study 
Days 1, 4, 7, and 10, respectively. For lo gistical reasons, the interval between periods may be extended by up to 2
days to accommodate site schedules.  The minimum washout between periods is 3days.  
Screening (Visit 1) will include procedures to access subject eligibility including clinical lab oratory  tests, phy sical 
examination, and driving simulation training/screening . Prior to randomization, subjects will be screened for 
simulato r sickness and will receive standardized training on the driving simulator and cognitive test battery. 
Screening procedures and screening assessments may be performed on different days but must be completed within 
28 days before Period 1 (Visit 2). The training drives on the driving simulator must be completed no more than 21 
days prior to the first dose of study d rug. 
Study drug or placebo will be administered by site staff during each period at 0 (Dose 1), 6 (Dose 2), and 10 
(
Dose 3) hours on Day  1 and at 22 hours (Dose 4) on Day 2 according to the treatment sequence assigned. Subjects 
will wear a blindfold when taking each dose to maintain the blind. The tablet size and shape are deemed similar 
enough to maintain the blind provided the subject is blindfolded.  Driving assessments commence at 8, 12 ,and 
24hours after Dose 1 .
The positive control (d iphenhydramine 50 mg) is included to establish the sensitivity of the study endpoints.
Treatment Arms:   
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 10
LY573144Treatment Sequences:
Subjects will be assigned and dosed with study medication (lasmiditan, d iphenhydramine ,or placebo) accor ding to 
the treatment sequence they are randomized to.  Subjects will be randomized equally into 1of 4 treatment 
sequences: 
Treatment 
SequencePeriod 1 Period 2 Period 3 Period 4
1Placebo Lasmiditan 100 mg Diphenhy dramine 50 mgLasmiditan 200 
mg
2Lasmiditan 100 mg Lasmiditan 200 mg PlaceboDiphenhy dramine 
50 mg
3 Lasmiditan 200 mg Diphenhy dramine 50 mg Lasmiditan 100 mg Placebo
4Diphenhy dramine 50 mg Placebo Lasmiditan 200 mgLasmiditan 100 
mg
Duration of Study: 
On Day  -1, prior to the first dose administration (the evening of clinical research unit [CRU] admission) subjects 
will complete a 20- minute practice drive on the CRCDS -MiniSim and a practice trial on the CogScreen SDC test.
Period 1, Day 1 subjects will be administered Dose 1 between approximately 0700 hours (7:00 AM) and 1000 hours
(10:00 AM) .  On subsequent dosing days of Periods 2 to 4, doses will be administered at approximately the same 
time of day as doses in Period 1.
Approximately 8hours following Dose 1, subjects will perform the CogScreen SDC test, KSS, and indicate their 
self-perceived safety to drive. Subjects will then perform the Country Vigilance -Divided Attention driving scenario 
on the CRCDS -MiniSim. Upon completion of the driving scenario ,subjects will be administered a VAS to assess 
subjects ’motivation and self -appraisal of their driving performance. Subjects repeat this testing procedure at 
approximately 12 hours and 24 hours after Dose 1 in all dosing periods .
Whil eresident at the CRU, lights out will occur at approximately 2300 hours (11:00 PM) every night.  
Subjects will remain a resident of the CRU from admission until discharge following the completion of study 
assessments. Blood draws for PKwill be taken at pre-and post -dose according to the schedule of activities in all 
periods . 

H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 11
LY573144The total duration of subject participation will be approximately 5 weeks (range 3 to 7 weeks).
Number of Subjects:
Approximately 72 subjects will be enrolled so that 60 healthy volunteers complete the study. This will lead to 90% 
or more power for testing each of the hypotheses of primary interest regarding the driving assessment endpoints.
Statistical Analysis:
Safety:
Safety analysis will be based on all subjects e nrolled who receive at least 1 dose of study medication. The safety 
analy sis will evaluate AEs and additional safety parameters. The number and percentage of subjects experiencing at 
least 1AE will be summarized by body system, preferred term, and treat ment. If appropriate, AEs will also be 
summarized by intensity and relationship to study drug. Serious adverse event s, if any, will be tabulated. 
Additional safety parameters will be assessed from summaries of physical examinations, 12 -lead electrocardi ogram s 
and vital signs. Hematology, chemistry ,and urinalysis laboratory test results will be categorized relative to the 
normal ranges. The changes from baseline for each of these parameters at postdose time points will be presented. 
Complete listings and summary tables for all safety information including AEs, laboratory safety data, vital signs ,
and physical examination will be included in the study report. 
Pharmacokinetics:
Pharmacokinetic parameter estimates for lasmiditan and its metabolites will be calculated using standard 
noncompartmental methods of analysis and summarized using descriptive statistics.  Plasma concentrations of 
diphenhydramine will be listed and summarized using descriptive statistics.
Pharmacodynamics: 
The primary endpoint, SD LP, will be analyzed using a mixed model with fixed effects for sequence, period, and 
treatment, and a random effect for subject within sequence for each of the driving time points . Secondary endpoints 
will be evaluated similarly ;however ,Lane Exceedance will be log transformed (more specifically ln[x+1 ]) prior to 
analy ses. Pairwise comparisons for readiness to drive will be analyzed using McNemar test. 
Graphical analyses will be performed to explore the relationship between PK concentrations with SDLP and/or other 
pharmacodynamic (PD)measures.  Additional analyses may be performed to further characterize the PK/PD 
relatio nship(s), if warranted.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 12
LY5731442.Schedule of Activities
Screening Study Informed Consent
Medical History 
Subject Eligibility
Weight/Height (BMI)
Drug and Alcohol Screen (repeat alcohol screen prior to Driving 
Sim Training/Practice if performed at a separate visit)
Vital Signs
Physical Examination ( may be performed through Day -1)
Epworth Sleepiness Scale
Clinical Laboratory Tests
Twelve -Lead ECG
Temperature
Serum Pregnancy Test (females only)
CogScreen SDC Training/Screening
Driving Sim Training/Screening
Simulato r Sickness Questionnaire
Concomitant Medication assessment
Day -1 (Period 1) Admission to Clinic
Confirm Subject Eligibility
Drug and Alcohol Screen
Serum Pregnancy Test (females only)
Vital Signs
Directed Physical Examination (symptom driven)
CogScreen SDC Practice
Driving Sim Practice
Adverse Event Assessment
Concomitant Medication Assessment (monitor throughout study)
Day 1 (Periods 1 -4) Predose
Vital Signs
Directed Physical Examination (symptom driven)
Lasmiditan and Metabolites PK Sampling (predose)
Diphenhy dramine PK Sampling (predose)
+0.0 h Study Drug Administration (Dose 1)
+0.5 h Lasmiditan and Metabolites PK Sample a
+1.0 h
Lasmiditan and Metabolites PK Sample a
Breakfast
+1.5 h Lasmiditan and Metabolites PK Sample a
+2.0 h Vital Signs/Lasmiditan and Metabolites PK Sample a
+3.0 h Lasmiditan and Metabolites PK Sample a
+4.0 h
Vital Signs/Lasmiditan and Metabolites PK Sample a
Lunch
+6.0 h
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 13
LY573144Lasmiditan and Metabolites PK Sample a
Study Drug Administration (Dose 2)
+8.0 h
KSSb
Adverse Event Assessment b
CogScreen SDC Test b
Self-Perceived Questionnaire (safe to drive)
Lasmiditan and Metabolites PK Sample a
Diphenhy dramine PK Sample a
CVDA Drive
VAS (immediately after drive)
+10.0 h
Lasmiditan and Metabolites PK Sample a
Study Drug Administration (Dose 3)
+11.0 h Dinner
+12.0h
KSSb
Adverse Event Assessment b
CogScreen SDC Test b
Self-Perceived Questionnaire (safe to drive)
Lasmiditan and Metabolites PK Sample a
Diphenhy dramine PK Sample a
CVDA Drive
VAS (immediately after drive)
Day 2 (Periods 1 -4) +22 h Study Drug Administration (Dose 4)
+23 h Breakfast
+24 h
KSSb
Adverse Event Assessment b
CogScreen SDC Test b
Self-Perceived Questionnaire (safe to drive)
Lasmiditan and Metabolites PK Sample a
Diphenhy dramine PK Sample a`
CVDA Drive
VAS (immediately after drive)
+36 h Lasmiditan and Metabolites PK Sample a
Day 3 (Periods 1 -4) +48 h Lasmiditan and Metabolites PK Sample a
Discharge (Day 3, 
Period 4)Discharge from 
Clinical Unit
Vital Signs
Physical Examination
Clinical Laboratory Tests
Adverse Event Assessment
Concomitant Medication Assessment
Early  Discontinuation
Vital Signs
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 14
LY573144Physical Examination
Clinical Laboratory Tests
Twelve -Lead ECG
Urinaly sis Samples 
Serum Pregnancy Test (females only)
Adverse Event Assessment
Concomitant Medication assessment
Within 5 to 9 days 
after DischargeFollow -up
Vital Signs
Physical Examination
Clinical Laboratory Tests
Twelve -Lead ECG
Urinaly sis Samples
Serum Pregnancy Test (females only)
Adverse Event Assessment
Concomitant Medication Assessment
Abbreviations:  BMI = body mass index; CVDA = Country Vigilance -Divided Attention ; ECG = electrocardiogram; 
h = hours, KSS = Karolinska Sleepiness Scale; PK = pharmacokinetic ; SDC = Symbol Digit Coding ; VAS = 
Visual Analog Scale .
aPharmacokinetic and pharmacodynamic sampling times are given as targets to be achieved within reasonable 
limits.  For PK sampling scheduled prior to driving assessments, the sampling window should be within -5 min to 
avoid conflict with driving assessment.  Otherwise, the sta ndard PK sampling windows: predose: -15 minutes; 
>0 to 2 hours postdose: ±5 minutes; 2.5 to 6 hours postdose: ±10 minutes; 7 to 12 hours postdose: ±20 minutes; 
>12 hours postdose: ±30 minutes.  The samples will be taken as per schedule to maintain the bli nd but samples 
will be analyzed according to the randomi zation table .
bThis accompanying driving assessment procedure should occur within -30 minutes before the scheduled CVDA 
drive targeted for this sampling time
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 15
LY5731443.Introduction
Lasmiditan is being developed by Eli Lilly and Company (Lilly) for the acute treatment of 
migraine attacks with or without aura in adults. This mo lecule has been developed by Lilly as 
LY573144 and by  CoLuci d Pharm aceuti cals, Inc.as COL -144 under the Invest igational New 
Drug application 103420.   Full details of lasm iditan’spreclinical and clinical safet y and 
tolerabilit y informat ion are contained in the Invest igator’s Brochure (IB).
3.1. Study Rationale
Lasmiditan is a highly select ive and potent agonist at the 5 -hydroxytryptamine (
5-HT)1Freceptor 
and is under development as a neurally act ing treatment for migraine.  The most frequent ly 
reported adverse events (AEs) ident ified in the lasmiditan clinical development program are 
central  nervous system (CNS )in nature based on the mechanism of act ion of the drug .  Due to 
treatm ent-related adverse effects of dizziness and fatigue observed in the Phase 2 clinical 
program, Study  COL -
MIG- 106/H8H -MC-LAHG (106/LAHG) evaluat ing the impact of 
lasmiditan on driving performance was conducted in accordance wit h the United States Food and 
Drug Administration (FDA) ’sEvaluat ing Drug Effects on the Abilit y to Operate a Motor 
Vehicle: Guidance for Industry  (2017)
Study  106/LAHG was a rando mized, subject -and investigator -blind ,placebo -controlled ,
five- period,crossover study wit h the following treatments:
Lasmiditan 50 mg
Lasmiditan 100 mg
Lasmiditan 200 mg
Alprazo lam 1 mg (posi tive control )
Placebo
Subjectswere randomized equally into 1of 10Latin square treatment sequences. The five 
periods were approximately 7 days in duration. 
The simulated driving test was commenced 90 minutes after dosing (on Days 1, 7, 14, 21, and 
28).
The effect of lasmidi tan on simulated driving performance was primarily  measured by the
standard deviat ion of lateral posit ion (SDLP )using the Cogni tive Research Corporation Driving 
Simulator (CRCDS )
-MiniSim.  During testing, subjects were instructed to drive a 100 -km 
highway segment with steady  lane posi tion and constant speed with a primary  outcom e measure 
of vehicle control , the SDLP (i.e. amount of “weaving” of the car in the lane). 
Driving performance as assessed by SDLP was inferior for lasmiditan 50 mg, 100 m g, and 
200mg relat ive to placebo. This was further confirmed by symmetry  analysis. Amajority of 

H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 16
LY573144subjects exceeded the impairment thresho ld (4.4 cm, co mparable to 0.05% b lood alcohol count 
[BAC]) at even the lowest dose of lasmiditan.  Sensit ivity of the simulator and the model used in 
the research design w eresupported by  significant findings on primary  and secondary  driving 
endpo ints for alprazo lam 1.0 m g. 
Secondary  driving endpoints provide further support to the conclusio n that l asmidi tan 50 m g, 
100mg,and 200 mg at 1.5 hours postdose had an adverse impact on simulated driving 
perform ance.
The time interval in 106/LAHG was chosen to capture the effect at the time of the peak 
concentration of lasmiditan and major metabo lites M7 and M8, in accordance with the FDA 
guidance .  However, the point at which patients should resume operation of a motor vehicle after 
taking lasmiditan is still unclear.  The primary  objective in the current study  is to determine the 
durati on of  effect of lasmiditan compared to pl acebo on simulated driving performance in 
healt hy subjects as measured by SDLP using the CRCDS -MiniSim at 8, 12, and 24 hours after 
dosing wit h lasmidi tan.  The 90- minute postdose simulated driving assessment used in 
106/LAHG will not be repeated in the current study .  For t he posit ive control , diphenhydramine 
treatm ent doses will be administered 2 hours prior to driving assessments to ensure the maximum 
cogni tive and sedat ive effect of the posit ive control (Ramaekers andO’Hanlo n 1994). 
3.2. Background
Lasmiditan is being invest igated for the acute treatment of migraine in adult s with and wi thout
aura.  Lasmiditan is a high -affini ty, highly  select ive 5 -HT (serotonin) 1Freceptor agoni st that i s 
being developed as a novel therapy for the acute treatment of migraine.  It has a chemical 
structure and pharmaco logic profile that i s dist inct fro m the triptans, t he current standard of care 
for the treatm ent of acute migraine .  Lasmidi tan does not contain the indole group observed in all 
triptans ;instead it has a py ridinoyl
-piperi dine scaffol d, which is unique to antimigraine 
medicat ions.  Lasmiditan is a low -molecular weight 5 -HT1Freceptor agonist with a nonvascular, 
primarily neural mechanism o f action.  It has high affinit y for the human 5-HT1Freceptor and 
>470 -fold select ivity for the human 5 -HT1Freceptor relat ive to the 5
-HT1Breceptor.  Across the 
completed Phase 1, 2, and 3 clinical studies, lasmidi tan doses of 0.1 mg to 400 m g were 
evaluated in healt hy subje cts or pati ents wi th migraine. In two Phase 3 ,placebo -controlled 
studi es in which patients treated 1 migraine attack with oral lasmiditan (50, 100 ,or 200 m g)or 
placebo, the most frequent ly reported lasmiditan treatment -emergent adverse events (TEAEs) 
weredizziness, paresthesia, somno lence, fatigue, lethargy , and nausea. A ma
jority of these 
TEAEs were mild or moderate in severit y.  In healthy  subjects, peak plasma concentrations of 
lasmiditan were observed approximately 1.5 hours to 2.5 hours after a s ingle oral dose ranging 
from 25mg to 400 m g, and the geom etric mean terminal half -life was approximately 4 hours.  
Lasmiditan pharm acokinetics ( PK)was approximately dose linear.
Following oral  dosing wi th lasmidi tan, up to 11 metabolites , including 3 maj or metaboli tes (M7, 
M8, and M18) ,were detected in human plasma and urine.  These metabo lites lacked significant 
pharmaco logical act ivity at the 5 HT 1Freceptor and were generally considered to be 
pharmaco logically inact ive.  The relat ive proportions o f metabolites to intact l asmidi tan 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 17
LY573144remained reasonably constant throughout the oral dose range studied and their PK was 
approximately  linear.  The half -life of the m etabo lites ranged fro m ~4.5 hours to 21 hours.
3.3. Benefit/Risk Assessment
The primary  object ive of this study  is to determine the duration of effect of lasmiditan on 
simulated driving performance in healthy subjects.  There is no anticipated therape utic benefi t 
for the healt hysubjects .
Lasmiditan has been generally well tolerated by healthy  subjects as single oral  doses up to 
400mg wit h no drug- related serious adverse events (SAEs) or withdrawals due to AEs in 
completed Phase 1 tri als (as of 01 Nov 2017) .  Dosing of lasmiditan and diphenhydramine will 
be conducted in an inpat ient setti ng, and subjects will be mo nitored in the clinical research unit 
(CRU) for the length of the study  until  discharge on Day  3, Peri od 4.
More informat ion about the known and expected benefits, risks, SAEs, and reasonably 
anticipated AEs of lasmiditan isto be found in the IB.  
More detailed informat ion about the known and expected benefits and risks of diphenhydramine 
may be found on the package informat ion.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 18
LY5731444.Objectives and Endpoints
Table LAIF .1shows the objectives and endpo ints of the study .
Table LAIF.1. Objectives and Endpoints
Objectives Endpoints
Primary
To determine the duration of effect of acute doses of 
lasmiditan 100 mg and 200 mg compared to placebo 
on simulated driving performance in healthy subjectsStandard deviation of lateral position (SDLP) using the 
Cognitive Research Corporation Driving Simulator -
MiniSim (CRCDS -MiniSim) at 8,12, and 24 hours 
postdose
Secondary
To determine the effects of lasmiditan 100 mg and 
200 mg compared to placebo on
self-reported endpoints Sleepiness endpoint -KSS
Self-reported readiness to drive (“Right now do 
you feel safe to drive?)
VAS to assess subject’s motivation and 
self-appraisal of their driving performance
performance endpoints, and CogScreen SDC test
Number of correct responses
Response accuracy
Standard deviation of reaction time
driving performance endpoints Lane exceedance ,including number, maximum, 
duration, and area of exceedance
Average speed, speed deviation, speed count
Excessive Ay (cornering speed threshold 
exceeded)
Total collisions
DA: correct responses, omission errors, 
commission errors, reaction time, standard 
deviation of reaction times
To evaluate the PK of lasmiditan in healthy subjects 
following a single 100- or 200 -mg oral dose of 
lasmiditanPK parameters:
oCmax, 
otmax, and 
oAUC(0 -∞)
Exploratory
To determine theeffect of acute doses of lasmiditan 
100 mg and 200 mg at 8, 12, and 24 hours compared 
with positive control (diphenhydramine 50 mg) at t maxSDLP using the CRCDS -MiniSim at 8, 12, and 24 hours 
To determine the effects of lasmiditan 100 mg and 
200 mg compared with positive control 
(diphenhydramine 50 mg) on :
self-reported endpoints, Sleepiness endpoint -KSS
Self-reported readiness to drive (“Right now do 
you feel safe to drive?)
VAS to assess subject’s motivation and self -
appraisal of their driving performance
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 19
LY573144performance endpoints, and CogScreen SDC test
Number of correct responses
Response accuracy
Standard deviation of reaction time
driving performance endpoints Lane exceedance ,including number, maximum, 
duration, and area of exceedance
Average speed, speed deviation, speed count
Excessive Ay (cornering speed threshold 
exceeded)
Total collisions
Divided attention (DA): correct responses, 
omission errors, commission errors, reaction time, 
standard deviation of reaction times
To evaluate the PK of diphenhydramine Diphenhy dramine concentrations
To evaluate the PK of lasmiditan metabolites M8, 
M7, and M18PK parameters:
oCmax, 
otmax, and 
oAUC(0 -∞)
Abbreviations:  AUC(0 -∞)= area under the concentration versus time curve from zero to infinity; Cmax= maximum 
observed drug concentration ;CRCDS = Cognitive Research Corpora tion Driving Simulator; DA = divided 
attention; KSS = Karolinska Sleepiness Scale ; PK = pharmacokinetics; SDC = Symbol Digit Coding ; SDLP = 
standard deviation of lateral position ; tmax= time of maximum observed drug concentration; VAS = Visual 
Analog Scale.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 20
LY5731445.Study  Design
5.1. Overall Design
This study  is a m ulticenter, randomized, subject -and invest igator -blind, active -and pl acebo -
controlled Williams square design wit h 4-period (f ull) crossover using a single dose of 
lasmiditan (Figure LAIF. 1).  Subj ects will  be randomized to treatment sequences and shoul d
complete all  4 periods wi thin that treatm ent sequence.
Figure LAIF. 1. Study schematic .
Study  governance considerations are described in detail in Appendix 3 .
5.2. Number of Participants
Approximately  72 healt hy subjects m ay be enrolled so that at least 60 healthy vo lunteers 
complete the study .  Forthe purposes of this study , a subject completes the study  when all  
scheduled procedures shown in the Schedule o f Activit ies (Secti on 2)have been completed.
5.3. End of Study Definition
End of the study  is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on
 2) for the last subject .
5.4. Scientific Rationale for Study Design
Subjects will enter the CRU on Day  
-1.  For the duration of the 4-period study , subjects will 
remain in the CRU .  Each period will  be of 3 days durati on.  It i s ant icipated that Study  
Periods 
1, 2, 3, and 4 will commence on Study  Days 1, 4, 7, and 10, respectively. For l ogist ical reasons, 
the interval between periods may be extended by up to 2days to accommoda te site schedules.  
The minimum washout between periods is 3 days.  Cogni tive testi ng and driving simulat ion will 
be conducted approximately 8, 12, and 24 hours afterDose 1 on Day  1 of each study  period.  
These driving assessment time po ints are expected to provide a wide range of responses 
including reversal o f impairment.
The study  design incorporates a positive control  (diphenhydramine 50 mg) to confirm assay 
sensit ivity.  Per the FDA ’sEvaluat ing Drug Effects on the Abilit y to Operate a Motor Vehicle: 
Guidance for Industry  (2017) , sedating antihistamines are commo nly used to understand the 
magnitude and duration of impairment.  Diphenhydr amine is a well -known sedat ing 
antihistamine available over the counter in the US and has been shown to have a significant Screening
•Subject 
EligibilityAdmission to 
Clinic (Day -1)
•Confirm 
Eligibility
•Driving 
Assessment 
PracticePeriod 1
•3 Days
•Driving 
Assessments 
(8, 12, and 24 
hours)Period 2
•3 Days
•Driving 
Assessments 
(8, 12, and 24 
hours)Period 3
•3 Days
•Driving 
Assessments 
(8, 12, and 24 
hours)Period 4
•3 Days
•Driving 
Assessments 
(8, 12, and 24 
hours)Discharge
•After all 
assessments 
on Day 3, 
Period 4
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 21
LY573144effect on driving performance ( Kay et al . 1997 ,2016 ).  Di phenhydramine will be administered 
no m ore frequent ly than every 4 hours pe r package direct ions, coinciding with time po ints 2 
hours pri or to each driving assessment so that the maximum cognit ive and sedat ive effect of the 
positive control  coincide wit h the initiation of the driving simulat ion task.
5.5. Justification for Dose
The upper lasmiditan dose level o f 200mg has been generally well tolerated in previous studies 
onhealt hy subjects and patients enrolled in the completed Phase 3 program and is anticipated as 
the highest recommended dose for lasmiditan.  The therapeutic dose ran ge al so includes 100 mg 
lasmiditan ,which will be evaluated in the current study  to expl ore any  differences in the duration 
of driving impairment effect.
Diphenhydramine is an over -the-counter antihistamine medicat ion for the treatment ,asa
temporary  relief ,of runny nose, i tchy andwatery  eyes ,sneezing anditching of the nose or throat 
due to hay  fever or other upper respi ratory allergies ,or runny nose and/or sneezing due to 
commo n cold.  The recommended dosage of diphenhydramine includes 50 m g taken every 4 to 
6hours.  Urine drug screen and alcoho l screen tests will be conducted on all potential subjects. 
Serum  pregnancy tests will be conducted on all female subjects. 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 22
LY5731446.Study  Population
Only medically  healthy subjects with clinically  acceptabl e laboratory  profiles and 
electrocardi ogram s (ECGs) will be enrolled in to the study . The informed consent documents 
will be discussed with each potential part icipant, and each individual will sign an informed 
consent document for the study  prior to any study -specific procedures being performed.
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening procedures and screening assessments may be performed on different days but m ust 
be co mpleted within 28 days prior to enrollment.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, isnot permitted.
6.1. Inclusion Criteria
Subjects are eligible for incl usion in the study  only if they  meet all  of the f ollowing criteria at 
screening. Continued eligibilit y will  be assessed through serum  pregnancy  (females only) and 
screen ingfor alcoho l and drugs of abuse on the day o f admissi on.
[1] are overtly healt hy males or females, as determined through medical history  
and physical examinat ion.
[1a] male subjects:
are not required to adhere to con tracepti ve requi rements.
[1b] female subjects: 
of childbearing potential, must test negative for pregnancy  at screening, and agree to 
use a reliable method of birth control during the study  from admissio n and for 
30days following the l ast dose of study  drug. Reliable methods of contraception for 
fema le subjects of childbearing potential include the use of stable hormonal 
contraception (including hormonal intrauterine devices) for at least 28 day s prior to 
admis sion.
of childbearing potential who are abstinent (if this is co mplete abst inence, as their
preferred and usual lifest yle) or in a same sex relatio nship (as part of their preferred 
and usual lifest yle) must agree to either remain abstinent or stay in a same sex 
relationship without sexual relat ionships wit h males. Periodic abstinence (e.g., 
calendar, ovul ation, symptothermal, post -ovulation methods), declarat ion of 
abstinence just for the duration of a trial, and wit hdrawal  are not acceptable methods 
of contracepti on. 
of non-childbearing potential, i.e., postmenopausal or permanent ly sterile f ollowing 
hysterectomy, bilateral salpingectomy, or tubal ligation, as determined through
medical history . Surgi cal tubal occl usion (i.e., Essure ®) is also an acceptable form 
of surgi cal sterilizat ion, provided the procedure was completed at least 3 months
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 23
LY573144prior to enro llment. Postmenopausal is defined as spontaneous amenorrhea for at 
least 12 m onths, and a fo llicle -stimulating horm one l evel greater than 40 m IU/mL, 
unless the subject is taking hormone replacement therapy (HRT). 
[2] are between the ages of 21 and 50 y ears (inclusive).  Attempts will be made to 
enrollno m ore than 60% of 1gender in the study .
[3] are able to reliably perform study  assessments (SDLP no higher than 1 
standard deviat ion [SD] greater than the mean for normal healt hyadults 
completing the practice scenario; Symbol Digi t Coding [SDC ]Corre ct no less 
than 1 SDbelow the mean for healthy adults in their age range); demo nstrate 
the abilit y to understand task instructions ;and arephysically capable ( e.g.,
adequate manual dexteri ty, visi on, and hearing) and cognitively capable of 
performing study  tasks.
[4] possess a valid driver’s license and is an active driver sat screening. Drive na 
minimum o f 8,000 miles (about 13,000 km) per year for the preceding 3 years.
[5] must a lso dem onstrate sufficient simulator sickness questionnaire scores ,
which are not indicat ive of simulator sickness as defined in the driving 
simulat ion operations manual.
[6] have a regul ar sleep pattern, and in general, have at least 7 hours of sleep each
night (bedtime occurs between 2100 hours and 2400 hours).
[7] have a score of<10 on the Epworth Sleepiness Scale.
[8] have a body  mass index (BMI) of 18 kg/m2to 35 kg/m2, incl usive 
[9] have clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igative site, or results with acceptable deviat ions that are 
judged to be not clinically significant by  the investigator.
[10] have venous access sufficient to allow for blood sampling as per the protocol.
[11] are reliable and willing to m ake themselves available for the duration of the 
study  and are willing to follow study  procedures.
[12] are able and willing to give signed informed consent.
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[13] are invest igative site personnel direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spo use, biological or 
legal guardian, child, or sibling.
[14] are Lilly  empl oyees or are em ployees of any  third party  involved in the study  
who require exclusio n of their emplo yees.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 24
LY573144[15] are currently enrolled in a clinical study  involving an invest igational product 
or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
[16] have participated, within the past 30 days of admission, in a clinical study  
involving an invest igational product.  If the previous invest igational product 
has a l ong half -life, 5 half -lives or 30 days from 
last dose (whichever is 
longer) should have passed .
[17] have previously completed or withdrawn fro m this study  or any  other study  
investigat ing lasmiditan, and have previously rece ived the invest igational 
product. 
[18] have known allergies to lasmiditan , related com pounds ,or any  com ponents of 
the form ulation, diphenhydramine , or a history  of significant atopy .
[19] have an abnormal blood pressure (BP) and/or pulse rate as determin ed by  the 
investigator.
[20] have a history  or presence of or significant history  of current cardiovascular, 
respi ratory , hepat ic, renal, gastrointestinal, endocrine, hematological, or 
neuro logical disorders capable of significantly altering the absorption , 
metabo lism, or eliminat ion of drugs; of const ituting a ri sk when taking the 
investigat ional product; or of interfering wit h the interpretation of data . 
Appendectomy, splenectomy, and cholecystectomy  are considered as 
acceptable.
[21] have a history  within 3 mo nths of admissio n, or current treatment for, a 
sleeping disorder (including excessive snoring, obstructive sleep apnea), or a 
chronic painful condit ion that interferes with the subject’s sleep.
[22] have a history  of difficult y either falling asleep or staying asleep in the 
previous 3 months o f admissio n that i s considered clinically significant by  the 
investigator.
[23] have a history or diagnosis of any  of the f ollowing condi tions:
i. primary  or secondary  insomnia
ii. narcolepsy
iii. cataplexy  (familial or id
iopathic)
iv. circadian rhythm sleep disorder
v. parasomnia including nightmare disorder, sleep terror disorder, sleepwalking 
disorder, and rapid eye movement behavior disorder
vi. sleep-related breathing disorder (obstructive or central sleep apnea syndrome, 
centr al alveol ar hypovent ilation syndrome)
vii. periodic limb movement disorder
viii. restless legs syndro me
ix. primary  hyperso mnia
x. excessive daytime sleepiness
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 25
LY573144xi. visual or auditory  impairment which in the opinion of the invest igator would 
interfere wi th study -related procedures or study  conduct.
[24] areexpected to use any  other m edicat ion or di etary suppl ement to prom ote 
sleep including over the -counter sleep medications, during their participat ion 
in the study .
[25] consume excessive amounts of coffee, tea, cola, or other caffeinated 
beverages per day .Excessive amount is defined as greater than 6 servings (1 
serving is approximately equivalent to 120 mg of caffeine).
[26] have traveled across 2 or more time zones (transmeridian travel) in the past 
2
weeks prior to randomizat ion.
[27] have work edin a night shift in the past 2 weeks prior to randomization .
[28] show a history  of CNS condi tions such as strokes, transient ischemic attacks, 
significant head traum a, seizures, CNS infect ions, migraine, brain surgery, or 
any other neurological condit ions that, in the opinion of the invest igator, 
increase the risk of participat ing in the study .
[29] have a known contraindicat ion to di phenhydramine such as myasthenia gravis, 
epilepsy  or sei zure disorders, narrow -angle glaucom a, prostati c hypertrophy , 
urinary  retent ion, asthma, bronchit is or chronic obstructive pulmo nary 
disease.
[30]ha
vea history  of orthostati c hypotensio n, faint ing spells, or blackouts that are 
considered clinically significant by  the investi gator.
[31]areintendingto use over -the-counter or prescript ion medicat ion, including 
dietary  supplements, within 14 days prior to dosing and unt il study  discharge 
(apart from occasio nal acetaminophen, hormonal contraception, or HRT).
[32] show evidence of significant active neuropsy chiatric disease (e.g. ,manic 
depressive illness, schizophrenia, depressio n) considered as clinically 
significant by  the invest igator.
[33] currently use or show evidence of substance abuse (including alcoho l abuse) 
or dependence within the past 6 m onths based on history  at screening visit.
[34] show evidence of human immunodeficiency  virus (HIV) infecti on and/or 
positive human HIV ant ibodies.
[35] show evidence of hepatit is C and/or positive hepat itis C ant ibody . 
[36] show evidence of hepat itis B and/or positive hepat itis B surface antigen. 
[37] are wom en who are lactating.
[38] have donated blood of more than 500 mL within the previous 2 month sof 
study  screening. 
[39] aresmokersof more than 10 cigarettes or e -cigarettes, or 3 cigars or 3 pipes 
per day , and areunable to refrain fro m smoking while resident at the CRU.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 26
LY573144[40] have an average weekly  alcohol  intake that exceeds 21 units per week (males) 
and 14 units per week (females), or are unwilling to stop alcohol consum ption 
48 hours prior to admissio n in Period 1, and whil eresident at the CRU. At all 
other times, subjects must agree to consume no more than 2 unit s per day  
(1unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL o f 
distilled spirits).
[41] consume alcoho l on a regul ar basis (i .e., ≥5 times/week) within 2 hours of 
bedtime.
[42] inabilit y to comply wit h the di etary  regimen of the clinical research center.
[43] have a positive pregnancy  test at screening or Day  -1.
[44] areplanning to beco me pregnant during the study or within 1 mo nth of study  
completion.
[45] inabili ty to use adequate contraception (as defined in 
[1]of the Inclusio n 
Criteria) during the study .  Fem ale subjects m ust agree to use adequate 
contraception for 30 day s following the last dose of study  drug .
[46] in the opinio n of the invest igator or sponsor, are unsuitable for inclusio n in the 
study .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Criteria [1] through [12] define a healt hy population suitable for evaluat ion in this Phase 1 study.  
Criteria [13] and [14] prevent conflict of interest in study  parti cipants.  Cri teria [15] through [46] 
predominant ly exclude medical condit ions, m edicati on intol e
rance, and concomitant medicat ion 
use that m ay confound the assessment of study  endpoints. 
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects may undergo m edical  assessments and review of compliance with 
requi rements before continuing in the study .
6.3.1. Meals and Dietary Restrictions
During each confinement period, subjects will consume only food and beverages that are 
provi ded to them  by the CRU staff.  Standard meals (e.g. ,breakfast, lunch, dinner, and snack) 
will be provided to the subject s while resident at th e CRU.  Breakfast, lunch, and dinner will be 
provi ded according to the Schedule of Act ivities(Secti on 2) . 
6.3.2. Caffeine, Alcohol, and Tobacco
From  48 hours pri or to admissi on in Peri od 1, and whil eresident at the CRU, subjects are not 
allowed to
consume xanthine -or caffeine -
containing food and drinks
consume alcoho lic beverages
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 27
LY573144oAt all other times, subjects must agree to consume no more than 2 units 
per day  (1 uni t = 12 oz or 360 m L of beer; 5 oz or 150 mL of wine; 1.5 oz 
or 45 m L of dist illed spirits).
use tobacco products
6.3.3. Activity
From  48 hours pri or to admissi on in Peri od 1, and whil eresident at the CRU, subjects are not 
allowed to engage in strenuous activit y.
While resident at the CRU, lights out will occur at approximately  2300 hours (11:00 PM) every 
night.  
6.4. Screen Failures
Individuals who do not meet the driving simulat ion criteria (Inclusio n Cri teria [2]and [ 4 ]to [7]) 
for parti cipation in this study  (screen failure) m ay not be re -screened.  Individuals who do not 
meet other criteria or driving simulat ion Inclusio n Criterion[
3]for parti cipat ion in this study  
(screen failure) may be re -screened at the discret ion of th e invest igator.   Individuals may be 
re-screened 1 time.  The interval between screenings should be at least 1 week.  When the 
re-screening is performed, the individual must sign a new informed consent form (ICF) and will 
be assigned a new ident ification number.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 28
LY5731447.Treatment
7.1. Treatment Administered
This study  involves orally  administered l asmidi tan wi th placebo. Diphenhydramine will be 
administered as a posit ive control .  Table LAIF. 2shows the treatment regimens.
Lasmiditan , diphenhydramine, or placebo will be administered orally wit h approximately 
240mL of room temperature water according to the subject’s assigned treatment sequence 
(Table LAIF. 3) and at the time po ints specified in the Schedule of Act ivities (Secti on  2).  
Subjects will not be allowed to lie supine for 2 hours after dosing, unless clinically indicated or 
for study  procedures.
Table LAIF.2
. Treatments A dministered
Treatment Name Placebo Lasmiditan (100 mg) Lasmiditan (200 mg) Diphenhy dramine
Dosage Formulation Tablet Tablet Tablet Tablet
Unit Dose 
Strength(s)/Dosage 
Level(s)2 tablets (1 100-mg) tablets/
100 mg LY + 1 placebo 
tablet(2 100-mg) tablets/
200 mg LY(2 25-mg) tablets/
50 mg 
Table LAIF.3. Treatment Schedule
Treatment 
SequencePeriod 1 Period 2 Period 3 Period 4
1Placebo Lasmiditan 100 mg Diphenhy dramine 50 
mgLasmiditan 200 mg
2Lasmiditan 100 mg Lasmiditan 200 mg Placebo Diphenhy dramine 
50 mg
3 Lasmiditan 200 mg Diphenhy dramine 50 mg Lasmiditan 100 mg Placebo
4 Diphenhy dramine 50 mg Placebo Lasmiditan 200 mg Lasmiditan 100 mg
The invest igator or designee is responsible for
explaining the correct use of the investigational product(s) to the subject
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection, and
returning all unused medication sto Lilly  or its designee at the end of the study
Note : In some cases, sites may destroy  the m aterial  if, during the invest igative site select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials. 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 29
LY5731447.1.1. Packaging and Labeling
Each tablet of lasmiditan contains 100 mg of act ive ingredient and is provided as bulk supplies in 
bottles.  Di phenhydramine will be sourced by  the investi gative si te.
Both l asmidi tan and di phenhydramine tablets are small and round.  Placebo tablets are sim ilar in 
size and shape to both lasmiditan and diphenhydramine tablets, but con tain no active ingredient.  
Placebo tabl ets will  be provi ded in similar bulk bottles as lasmiditan.
The invest igational product swill be labeled according to the coun try’s regula tory requi rements.
7.2. Method of Treatment Assignment
The sponsor (or designee) will be responsible for generat ing each of the rando mizat ion schedules 
and distribut ing them direct ly to the CRU pharmacist.
7.2.1. Selection and Timing of Doses
The doses will be adminis tered at approximately  the sam e time on each day (Figure LAIF. 1).  
Period 1, Day  1 subjects will  be administered Dose 1 between approximately  0700 hour s (7:00 
AM) and 1000 hours (10:00 AM) .  For each subject, the same time o f Dose 1 in Period 1 should 
be targeted for Dose 1 in Periods 2 to 4 within reasonable limit s.  Subj ects are permitted, and 
encouraged, to engage in their normal sleep pattern between Dose s3 and 4. 
Figure LAIF. 2 Timing of doses .
The actual  time of all dose administrations will be recorded in the subject ’s case report form 
(CRF).
Treatment sequences will be determined using a repeated 4×4 Williams square design 
(Table 
LAIF .3).  The rando mizat ion schedule will be securely maintained by the study center 
pharmacist who is responsible for dispensing the bl inded study  medicati on in accordance with 
the schedule.  The sponsor (or designee) will be responsible for generating the rando mizat ion 
schedule and distribut ing them direct ly to the study center pharmacists.

H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 30
LY5731447.3. Blinding
Study  drugs (l asmidi tan, di phenhydrami ne, and/or pl acebo) will be prepared into individual 
dispensing containers by an unblinded pharmacist or designee and administered by  an unblinded 
staff member who will not be invo lved in any study  assessment procedures.  Each subject will be 
blindfo lded p rior to each dosing occasio n to m aintain the study  blind.  The unblinded staff 
member will hand the dispensing container to each subject, who will then self -administer all 
tablets in the di spensing container without touching any  of the tabl ets by  hand.  Ne ither the 
investi gator nor any  study  staff invo lved in the subject assessment will be allowed to witness the 
study  drug administrati on.  The blindfo ld will be removed before any assessments commence.
Blinding will be maintained throughout the conduct of th e study  as described in the separate 
Blinding Plan.
Emergency  codes will be available to the invest igator .  A code, which reveals the treatment 
sequence for a specific study  subject , may be opened during the study  only  if the subject ’s 
well-being requires knowl edge of the subject ’s treatment assignment.
If a subject ’sstudy  treatm ent assignment is unblinded, the subject must be discont inued from the 
study , unless the invest igator obtains specific approval fro m a Lilly clinical pharmaco logist or 
clinical research physician (CRP) for the study  parti cipant to continue in the study .  During the 
study , emergency  unblinding shoul d occur only by accessing the study  subject’s em ergency 
code.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent assi gnment i s warranted for m edical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.  If the 
investigator decides that unblinding is w arranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dose Modification
Dose m odificat ion will not be allowed during the study
7.5. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained, as communicated by the sponsor, during transit for all invest igational product s
received and any  discrepancies are reported and resolved before use of the study  treatm ent.
Only participants enro lled in the study  may receive invest igational product sor study  materials, 
and only  authori zed si te staff may  supply  or administer in vestigational product s.  All 
investigat ional product sshould be stored in an environmentally controlled and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized site s taff.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 31
LY573144The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance (such as 
recei pt, reconciliat ion,and final disposit ion records).
7.6. Treat ment Compliance
The invest igational product swill be administered at the clinical site, and documentation of 
treatm ent administration will occur at the site.
7.7. Concomitant Therapy
In general, concomitant medicat ionsshoul d be avoided; however, acetaminophen (maximum 
3g/24 hours) may be administered at the discretion of the invest igator for the treatm ent of 
headache ,etc.  Contraceptive medicat ion is permit ted as per the inclusio n criteria.  Horm one 
replacement therapy  is also allowed.
If the need for concomi tant m edicat ion (other than acetaminophen, hormonal contraception, or 
HRT) ari ses, inclusio n or continuat ion of the subject may be at the discretion of the invest igator 
after consul tation wi th a Lilly clinical pharmaco logist, CRP, or designee.  Any medicat ion used 
during the course of the study  must be docum ented.
7.8. Treatment after the End of the Study
Not applicable.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 32
LY5731448.Discontinuation Criteria
Subjects discont inuing fro m the treatm ent prem aturely  for any reason shoul d com plete AEand 
other fo llow-up procedures per Section 2of this protocol .
Subjects discont inuing fro m the study  prematurely for any  reason must com plete AEand 
follow-up procedures per Section 2of this protocol.
8.1. Discontinuation from Study Treatment
Discontinuati on of  the invest igational product for abnormal liver test result s should be 
considered by the investigator when a subject meets 1 o f the following condit ions after 
consultation wit h the Lilly -designated m edical m onitor:
alanine aminotransferase ( ALT ),aspartate aminotransferase (AST ) >5X upper limit of 
norm al(ULN )for healt hy subjects ,or
ALT or AST >3X ULN for healthy  subjects susta ined for more than 2 weeks , or
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or internat ional 
norm alized ratio>1.5,or
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%), or
alkaline phosphatase (ALP ) >3X ULN, or
ALP >2.5X ULN and TBL >2X ULN, or
ALP >2.5XULN with the appearance of fatigue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%).
8.1.1. Discontinuatio n of Inadvertently Enrolled Subjects
If the sponsor or i nvest igator ident ifies a subject who did not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogistand the 
investigator to determin e if the subject may cont inue in the study .  If both agree i t is medically  
appropriate to continue, the invest igator must obtain documented approval fro m the Lilly clinical 
pharmaco logistto allow the inadvertent ly enrolled subject to conti nue in the study with or 
without continued treatment with invest igational product.
8.2. Discontinuation from the Study
Subjects will be discont inued under the following ci rcumstances:
Enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and go od clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the subject should be discontinued from the study
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 33
LY573144Subject Decisio n
othe subject requests to be withdrawn fro m the study.
8.3. Patients/Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact s ubjects who fail to return for a schedule d visit or were otherwise 
unable to be fo llowed up by  the si te.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 34
LY5731449.Study  Assessments and Procedures
Secti on 2 lists the Schedule of Act ivities, detaili ng the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that will be performed for t his study.
Appendix 5 provi des a summary  of the m aximum  number and vol ume of invasive samples, for 
all sampling, during the study .
Unless otherwise stated i n subsect ions below, all samples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, re gulations, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
This sect ion is not applicable for this study.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study .
Invest igators must document their revi ew of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or th at caused the subject to discontinue the invest igational product before 
completing the study.  The subject should be fo llowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow
-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
After the ICF is signed, study  site personnel will record, via eCRF, the occurrence and nature of 
each subject’s preexist ing condit ions, including clinically significant signs and symp toms of  the 
disease under treatment in the study .  Addi tionally , site personnel will record any  change in the 
condi tion(s) and the occurrence and nature of any AEs.  
The invest igator will interpret and document whether or not an AE has a reasonable possib ility 
of being related to the study treatment, or a study  procedure, taking into account the disease, 
concomitant treatment ,or pathol ogies.
A “reasonable possibilit y” means that there is a potential cause and effect relat ionship between 
the invest igational product, study  device ,and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 35
LY573144If a subject’s invest igational product is discont inued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via eCRF.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1of the f ollowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience ( i.e., immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi ze the subject or may requi re interventi on to prevent 1
of the other outcomes listed in the definit ion above.
Study  site personnel  must al ert the Lilly  CRP/ clinical pharmaco logist, or its desi gnee, of  any 
SAE as soon as practically possible.
Additionally , study  site personnel  must al ert Lilly  Global Patient Safet y, or its desi gnee, of any  
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.
Although all AEs are recorded in the e CRF after signing informed consent, SAE reporti ng to the 
sponsor begins after the subject has signed informed consent and has received invest igational 
product.  However, if an SAE occurs after signing informed consent, but prior to receiving 
investigat ional product , AND is considered Reasonably Possibl y Related to a study  procedure 
then it MUST be reported .
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued fro m and/or com pleted the study  (the subject summary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnancy (maternal or paternal exposure to investigat ional product ) does not meet the definit ion 
of an AE.  However, to fulfill regulatory  requi rements any pregnancy  should be reported 
following the SAE process to collect data on the outcome for b oth m other and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to invest igational product or procedure.  Lilly 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 36
LY573144has procedures that will be fo llowed for the recording and expedited reporting of SUSARs that 
are consistent with global regulations and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery  system s used in 
clinical trials in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to facilitate 
process and product improvements.
Subjects should be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdose
9.3.1. Overdose of Lasmiditan
For the purposes of this study , an overdose of l asmidi tan is considered any dose higher than the
dose assigned through rando mizat ion.  There is no specific antidote for lasmiditan.
In case of an overdose, it is recommended that the subject be monitored for si gns and symptom s 
of adverse reactions. Subject s who develop adverse reactions should receive appropri ate 
supportive therapy  and AEs shoul d be docum ented.
9.3.2. Overdose of Diphenhydramine
For the purposes of this study , an overdose of di phenhydramine is considered any  dose higher 
thanthe dose assigned through rando mizat ion.  Antihistamine overdosage r eactions may  vary 
from CNS depressio n to stimulat ion.  Atropine -like si gns and symptom s; dry  mouth; fixed, 
dilated pupils; flushing; and gastrointestinal symptoms may also occur.  In the event of a 
diphenhydramine overdose, the subject should receive appro priate m edical care.
9.4. Safety
9.4.1. Laboratory Tests
For each subject , laboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Section 2). 
9.4.2. Vital Signs
For each subject , vital sign measurements should be conducted according to the Schedule o f 
Activities (Section
 2).  
Blood pressure and pulse rate should be measured singly after at least 5 minutes supine.  For 
each individual subject, the same cuff size should be used throughout the study  for the 
measu rements of BP.  The cuff should be attached to the subject’s dominant arm.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  Where orthostatic measurements are required, subjects s hould be 
supine for at least 5 minutes and then subjects will stand, and standing BPwill be measured after 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 37
LY5731442 minutes; no longer than 3 minutes. If the subject feels unable to stand, supine vital signs only
will be co llected . 
Addit ional vital signs may b e measured during each study  period if warranted.
9.4.3. Electrocardiograms
For each subject , ECGs should be collected according to the Schedule of Activit ies(Secti on 2).  
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subject receives the first dose of the invest igational product should be reported to Lilly, or its 
designee, as an AE via e CRF . 
For each subject , a single12 -lead di gital ECG will  be collected according to the Schedule of 
Activities(Secti on
 2).  Electrocardi ograms m ust be recorded be fore collecting any blood 
samples.   Subjects must be supine for approximately  5 to 10 minutes before ECG collection and 
remain supine but awake during ECG collection.  Electrocardiograms may be obtained at 
additional times,when deemed clinically necessary .  All ECGs recorded should be stored at the 
investigat ivesite.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is still present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findin gs be 
ident ified.  
If a clinically significant finding is ident ified (including, but not limited to, changes in 
QT/corrected QT interval from baseline) after enrollment, the invest igator will determine if the 
subject can continue in the study .  The invest igator, or qualified designee, is responsible for 
determining if any change in subject management is needed, and must document his/her review 
of the ECG printed at the time of co llection.  Any  new clinically  relevant finding shoul d be 
reported as an AE.
9.4.4. Safety Monitoring
The Lilly clinical pharmaco logist or CRP/scient ist will mo nitor safety  data throughout the course 
of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly clinical 
pharmaco logist or CRP will periodi cally  review the foll owing data:
trends in safety  data
laboratory  analy tes 
adverse events 
When appropriate, the Lilly clinical pharmaco logist or CRP will consult wit h the funct ionally 
independent Global Pat ient Safety  therapeut ic area physician or clinic al research scient ist.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 38
LY5731449.4.4.1. Hepatic Safety
If a study  subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or el evated TBL ≥2X 
ULN, liver tests ( Appendix 4 ) shoul d be repeated wi thin 3 to 5 day s including ALT, AST, ALP, 
TBL, direct bilirubin, gamma -glutamyl transferase, and creatinine kinase to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens , clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator based on 
consultation wit h the Lilly clinical pharmaco logist or CRP .  Monitoring should continue unt il 
levels norm alize and/or are returning to approximate baseline levels. 
Addit ional safet y data should be co llected if 1 or more of the following condit ions occur: 
elevation of serum  ALT to ≥5X ULN on 2or more consecutive blood tests
elevation ofserum  TBL to ≥2X ULN (except for cases of known Gilbert’s
syndro me)
elevation of seru m ALP to ≥2X ULN on 2 or more consecutive blood tests
subject discontinued from the treatm ent due to a hepatic event or abnormalit y of
liver tests
hepat ic event considered to be a nSAE.
9.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Activities (Secti on 2), venous blood samples 
of
 approximately 2 mL each will be co llected to determine the plasma concentrations o f 
lasmiditan and  metabolites M7, M8, (S,R)-M18, and (S,S)-M 18.  Time of blood collect ion will 
be based on Dose 1.  Similarly, at times specified in the Schedule of Act ivities (Section 2), 2 
mL of venous blood samples will be collected to determine the plasma concentrations of 
diphenhydramine per Appendix 5  to confirm adequate washout and enable exploratory 
PK/pharmacodynamic  (PD) analysis.  A maximum of 3 samples may b e collected at addi tional 
time points during the study i f warranted and agreed upon between both the in vestigator and 
sponsor.  Instructions for the collect ion and handling of blood samples will be provided by the 
sponsor .  The actual d
ate and time (24 -hour clock time) of each sampling will be recorded.
Drug concentration informat ion that would unblind the study  will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.
Concentrations of lasmidi tan and i ts metaboli tes M8, M7, and M18 will be assayed using a 
validated liquid chro matography  tandem -mass spectrometry  (LC-MS/MS) method.  Analyses of 
lasmiditan samples collected from periods corresponding to placebo and positive control 
(diphenh ydramine) are not planned with the exceptio n of predose samples on Day  1 of each 
period.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 39
LY573144Concentrations of diphenhydramine will be assayed using a validated LC -MS/MS m ethod.  
Analyses of diphenhydramine samples co llected from periods corresponding to place bo and 
lasmiditan are not planned with the except ion of predose samples on Day 1 of each period.  
Bioanaly tical samples collected to m easure invest igational product concentrations will be 
retained for a maximum o f 2 years fo llowing last subject visit for the study .  During this time, 
samples remaining after the bioanalyses may be used for exploratory  analyses such as 
metabo lism and/or protein binding work.
9.6. Pharmacodynamics
9.6.1. Country Vigilance -Divided Attention Driving Scenario on the 
CRCDS -MiniSim
The presen t study empl oys the Country  Vigilance -Divided Attention (CVDA )driving scenario, a 
100-km two - lane highway  driving task that includes a secondary  visual  vigilance task (DA). The 
monotonous Country  Vigilance scenario has been demonstrated to be sensit ive to detect the 
effects of fatigue or sleepiness on driving performance. This scenario has been useful in 
measuring the effects of sleep deprivat ion, obstructive sleep apnea, chroni c primary  insomnia, 
and is sensit ive to CNS depressants (e.g., alcoho l and se dating ant ihistamines). Results obtained 
using this methodology  are com parable to those obtained using over -the-road driving tests 
(Siemen et al. 2015). 
Subjects will perform the driving simulator test at the times specified in the Schedule of 
Activities(Secti on 2) .  Data will be captured in electronic format. Details are provided in the 
Cogni tive Research Corporation CRCDS Testing Operations Man ual.
9.6.2. Karolinska Sleepiness Scale
The Karolinska Sleepiness Scale (KSS)
(Akerstedt andGillberg 1990) will be used to assess 
subjective level of sleepiness.  This is a subject self- report edmeasure of situat ional sleepiness 
and provides an assessment of alertness/sleepiness at a particular point in t ime.  The KSS has 
been found to correlate with electroencephalogram and behavioral variables (Kaida et al. 2006).
Subjects will self -report thei r KSS assessments at the times specified in the Schedule of 
Activities(Secti on 2) . The subject’s self -reported scores will be recorded in the eCR F.
9.6.3. Self-Perceived Safety to Drive Question
Prior to dri ving,the subject will be asked a simple question as to whether they  feel safe to drive 
(“Right now do y ou feel safe to drive?”). Subject will answer “yes” or “no”. 
The answer will be 
recorded in the eCRF.
9.6.4. CogScreen Symbol Digit Coding
Symbol Digit Coding will  be used in this study  to measure attention, visual scanning, working 
memory , and speed of informat ion processing. Symbo l Digit Coding is a com puter anal og of  the 
convent ional symbo l-subst itution task found in the WAIS -R Di git Symbo l subtest and the 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 40
LY573144Symbol Digit Modali ties Test (Wechsler 1981).  The SDC test will be administered by trained 
study  site personnel. Subjects will perform the test prior to the driving simulat ion test at the 
times spec ified in Section2.The subject will perform the test by  interacting with an electronic 
monitor screen. Data will be captured in electronic format.  Details are provided in the 
CogScreen ®Examiner Manual, CogScreen LLC, 2016.
9.6.5. Visual Analog Scale to Assess Subject’s Motivation and Self -
Appraisal
After complet ing the driving simulat ion, subjects will assess their own performance and their 
level of motivation to perform at their best during the driving simulat ion
.
Subjects will respond to 2 questions:
1. How well you think y ou drove for the last 60 minutes?
2. How m otivated di d you feel to drive at y our best during the last 60 minutes of driving?
Subjects will record their response to each quest ion by writ ing a ve rtical line on a 100 -mm 
horizontal , linear visual analog scale ,indicating their level o f performance (Not Sati sfactory  to 
Satisfactory ) and m otivat ion (Not Motivated to Motivated). Scores on the 100- mm linear scale 
will be measured to the nearest millime ter from the l eft. The subject’s scores will be recorded in 
the eCRF.
9.7. Genetics
This sect ion is not applicable for this study.
9.8. Health Economics
This sect ion is not applicable for this study.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 41
LY57314410. Statistical Considerations and Data A nalysis
10.1. Sample Size Determination
Approximately 72 subjects will be enrolled so that approximately  60 heal thy volunteers complete 
this study . This study  is designed to test noninferiority (NI) of lasmidi tan rel ative to placebo, 
with a diphenhydramine test versus placebo to c onfirm the sensit ivity of the simulator to detect 
treatm ent effects. The fo llowing assumpt ions were m ade in the sample size co mputation: (a) SD
of differences between lasmiditan and placebo within subject for SDLP is approximately  9.5 cm; 
(b) the true dif ference between lasmiditan doses and placebo is 0; and (c) the NI margin is 
proposed to be 4.4 cm, which is the effect seen with 0.05% of BAC. Under these assumpt ions, a 
sample of 60 subjects would provide >90% power to establish NIof either dose of l asmiditan 
compared to pl acebo in term s of the primary  end point, SDLP. This sam ple size is m ore than 
adequate to detect diphenhydramine differences, which are ant icipated to exceed the NI margin , 
from placebo .
Subjects who are randomized but who do not compl ete all  4 peri ods during the Treatment Phase 
may be replaced. Replacement subjects will enter the same treatment sequence as the original 
subjects to complete all 4 periods. 
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o fsubject disposit ion will be provided at the end of the study .
10.2.2. Study Participant Characteristics
The subjects’ year of birth, sex, weight, height, race, and other demographic characterist ics will 
be recorded. Age and BMI will be calculated. Demographic and baseline characterist ics will be 
summarized.
10.3. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee. Complete 
details o f the planned analyses will be contained in the s tatistical analysis plan.
Pharmacokinet ic analyses will be conducted on data fro m all subjects who receive at least 1 dose 
of the invest igational products and have evaluable PK.
Pharmacodynamic analyses will be conducted on data from all subjects who receive at least 1 
dose of the inve stigational products and have evaluable PD.
Pharmacokinet ic/pharmacodynamic analyses will be conducted on data from all subjects who 
receive at least 1 dose of the invest igational product sand have evaluable PK.  
Safety analyses will be conducted for all enrolled subjects ,whether or not they  com pleted all  
protocol  requi rements.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 42
LY573144Addit ional exploratory  analyses of the data will be conducted as deemed appropriate. In general, 
categori cal variables will be summarized by the count (N) and percentage of subjec ts (%). 
Continuous variables will be summarized by the number of non -missing observations (N), mean, 
SD, m edian, minimum, and maximum values. 
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All invest igational product and protocol procedure AEs will be lis ted, and if the frequency of 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with invest igational product as perceived by the investigator.  Symptoms reported to occur prior 
to enrollment will be dist inguished fro m those reported as new or increased in severit y during the 
study .  Each symptom will be classified by the most suitable term fro m the Medical Dictionary  
for Regulatory Activit ies.
The number of invest igational product -related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory parameters and vital signs.  The 
param eters will  be listed, and summarized using standard descript ive statist ics.  Addi tional 
analysis will be performed if warranted upon review of the data .
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Plasma concentrations o f lasmiditan, its metabo lites, and di phenhydramine will be listed and 
summarized using descript ive statist ics.
Pharmacokinet ic parameter estimates for lasmiditan and its metabolites will  be calculated using
standard nonco mpart mental methods of analysis and summarized using descriptive statist ics by 
dose l evel.
The primary  parameters for analysis will be maximum observed drug concentration (C max) and 
area under the concent ration versus time curve (AUC).  Other noncompart mental param eters, 
such as half-life, apparent clearance, and apparent vo lume of distribut ionmay be reported.
10.3.3. Pharmacodynamic Analyses 
The primary  endpoint, SDLP, will be analyzed using a mixed model wit h fixed effects for 
sequence, period, and treatment, and a random effect for subject within sequence for each of the 
driving t ime points. Separate models will be used for each of the driving time po ints.
Secondary  endpoints will be evaluated similarly ;howe ver,Lane Exceedance will be log 
transformed (more specifically , ln[x+1]) prior to analyses. Pairwise com parisons for readiness to 
drive will be analyzed using McNemar test.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 43
LY573144For the primary  and secondary  endpoints, pai rwise com parisons (hypothesis tests) of differences 
in means, and 95% confidence intervals on differences will be provided at each time point for
1.Lasmiditan 100 mg versus placebo
2.Lasmiditan 200 mg versus placebo
3.Diphenhydramine 50 mg versus placebo
In addi tion, pai rwise wi thin-subject differences in SDLP greater than 4.4 cm in abso lute value 
(equal  to the previ ously found difference between placebo and 0.05% BAC for the CRCDS) will 
be co mpared using McNemar test. Furthermore, these pairwise, within- subject differences in 
SDLP will be tested for symmetry  about zero using the maximally selected McNemar test.
10.3.3.1. Pharmacodynamic Statistical Inference
To address mult iplicit y of testing , 2doses of lasmiditan versus placebo at 3 time points for the 
primary  endpo int of SDLP, ascending doses of lasmiditan at descending time points will be 
interpreted in a sequent ia
l manner, starting with the 100 -mg dose at 24 hours and proceeding to 
the 200- mg dose and earlier time po ints via a graphical mult iple co mpar isons p rocedure ( Figure 
LAIF. 3). The value of w, the split of alpha after testing 100 mg at 24 hours, will be specified in 
the stati stical analysis plan.
Figure LAIF. 3. Pharmacodynamic statistical inference – graphical multiple 
comparisons procedure .
Doses of l asmidi tan will be considered noninferior to placebo at a time point if the upper 95% 
confidence limit on the difference in SD LP between that dose and placebo is less than 4.4 cm. 
No adj ustment to al pha levels will be made for the comparison of diphenhydramine either to 
placebo or to lasmiditan, or for secondary  endpoints or analyses. Form al statistical  tests (where 
performed) will be 2-sided wi th testing at the alpha=0.05 level o f significance.

H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 44
LY57314410.3.4. Pharmacokinetic/Pharmacodynamic Analyses
Graphical analyses may be perform ed to expl ore the relationship between PK concentrations 
with driving performance (i .e.,SDLP) and/or other PD measures.  Addit ional analyses may  be 
perform ed to further characterize the PK/PD relat ionship(s), if warranted.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 45
LY57314411. References
Akerstedt T, Gillberg M. Subject ive and object ive sleepiness in the active individual. Int J
Neurosci . 1990;52(1 -2):29-37.
CRCDS Testing Operat ions Manual. Cognit ive Research Corporation. Data on file.
[FDA] Food and Drug Administration. Evaluating Drug Effects on the Abilit y to Operate a 
Motor Vehicle Guidance for Industry (November 2017). Available 
at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformatio
n/Guida  
nces/UCM430374.pdf. Accessed January 16, 2018.
Kaida M, Takahashi T , Åkerstedt A, Nakata Y, Otsuka T, Haratani K, Fukasawa K . Validat ion 
of the Karo linska sleepiness scale against performance and EEG variables. Clin Neurophysio l.
2006 ;117(7):1574 -1581.
Kay GG, Berman B, Mockoviak SH, Morris CE, Reeves D, Starbuck V, Suken ik E, Harris AG. 
Initial and steady-state effects of diphenhydramine and loratadine on sedati on, cognition, 
mood, and psycho
motor performance. Arch Intern Med. 1997;157(20):2350-2 356. 
Kay GG, Schwartz HI, Wingertzahn MA, Jayawardena S, Rosenberg RP. Next -day residual 
effects of gabapent in, diphenhydramine, and triazolam on simulated driving performance in 
healt hy vo lunteers: a phase 3, randomized, double -blind, pl acebo -controlled, crossover trial. 
Hum Psychopharmacol . 2016 ;31(3):217-226.
Ramaekers JG , O’Hanl on, JF.Acrivast ine, terfenadine and diphenhydramine effects on driving 
perform ance as a funct ion of dose and time after dosing. Eur J Clin Pharmacol .
1994;47(3) :261- 266.
Siemen A, Gargano C, Cha J, Drexel M, Bautmans A, Heirman I, Laethem T, Hochadel T, 
Gheyle L, Bleys K, Beals C, Stoch A, Kay  G, Struyk A. A randomized, crossover, placebo -
controlled clinical trial to assess the sensit ivity of the CRCDS Mini -Sim to the nex t-day 
residual effects of zopi clone. Ther Adv Drug Saf .2015 ;6(3):86- 97. 
Steiner TJ, Stovner LJ, Birbeck GL .Migraine: the seventh disabler. Cephalalgia
.
2013; 33(5):289 -290.
Wechsler D. Wechsler Adult Intelligence Scale -Revised. San Antonio: Psychological
Corporati on;
1981.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 46
LY573144Appendix 1. Abbreviations and Definitions
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 47
LY573144Term Definition
5-HT 5-hydroxytryptamine
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase 
AST aspartate aminotransferase
AUC area under the concentration versus time cu rve
BAC blood alcohol count
blinding A procedure in which 1or more parties to the study are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single -blind study is one in which the investigator and/or his sta ff are aware of the 
treatment but the subject is not, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and/his staff and the subject are not. A double -blind study  is one in 
which neither the subject nor any of the investigator or sponsor staff who are involved in 
the treatment or clinical evaluation of the subjects are aware of the treatment received .
BMI body mass index
BP blood pressur e
CNS central nervous system
complaint A complaint is any written, electroni c, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be re -tested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRCDS -MiniSim Cognitive Research Corporation Driving Simulator -Min iSim
CRF case report form
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 48
LY573144CRP clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician ,or other medical officer.
CRU clinical research unit
CVDA Country  Vigilance -Divided Attention
DA Divided attention
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
FDA Food and Drug Administration
GCP good clinical practice
HIV human immunodeficiency virus
HRT hormone replacement therap y
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
Investigational 
New DrugAn application to the FDA to allow testing of a new drug in humans.
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study , after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate. Informed consent is documented by means of a 
written, sig ned,and dated informed consent form .  
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 49
LY573144investigator A person responsible for the cond uct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
KSS Karolinska Sleepiness Scale
LC-MS/MS liquid chromatography tandem -mass spectrometry
legal 
representativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject , to the subject’s participation in the clinical study.
NI noninfer iority
PK/PD pharmacokinetic/pharmacodynamic
randomize The process of assigning subjects to an experimental group on a random basis .
SAE serious adverse event
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SD standard deviation
SDC Symbol Digit Coding
SDLP standard deviation of lateral position
SUSAR suspected unexpected serious adverse reaction
TBL total bilirubin level
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment 
ULN upper limit of normal
VAS Visual Analog Scale
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 50
LY573144Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate (total CO 2)
Mean cell volume Chloride 
Mean cell hemoglobin Calcium 
Mean cell hemoglobin concentration Phospho rus 
Leukocytes (WBC) 
PlateletsGlucose (random )
Differential WBC (absolute counts )of Blood urea nitrogen (BUN)
Neutrophils Uric acid 
Lymphocy tes
Monocytes Total protein
Eosinophils Albumin
Basophils Total bilirubin
Alkaline phosphatase (ALP)
Urinalysis a Aspartate aminotransferase (AST)
Specific gravity Alanine aminotransferase (ALT)
pH Creatinine
Protein
Glucose
Ketones Ethanol testing b
Bilirubin Urine drug scree nb
Urobilinogen Hepatitis B surface antigen c
Blood Hepatitis C antibody c
Nitrite HIV c
Pregnancy test (females only)
FSH (if applicable )c
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cell; 
WBC = white blood cell.
aPerformed at follow -up and early  discontinuation only. 
bUrine drug screen and ethanol (urine or breath) level may be repeated prior to admission to the clinical research 
unitand at other times indicated in the Schedule of Activities (Section 2).
cPerformed at screening only . 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 51
LY573144Appendix 3. Study  Governance, Regulatory ,and 
Ethical Considerations
Informed Consent
The invest igator is responsible for
ensuring that the subject understands the nature of the study , the potential risks and 
benefits of part icipating in the study, and that their participat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  Thi s 
includes obtaining the a ppropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational 
product.
answering any quest ions the subject may have throughout the study  and sharing in a 
timely  manner any  new informat ion that m ay be relevant to the subject’s willingness to 
continue his or her participat ion in the study.
provi ding a copy  of the ICF to the participant or the participant’s legal representative and 
retaining a copy  on file.
Recruitment
Lilly or its designee is responsible for the central recruit ment strategy  for subject s.  Individual 
investigators may have addit ional local requirements or processes.  Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The invest igator or appropriate local representative must give assurance that the ethical review 
board ( ERB )was properly const ituted and convened as required by Internat ional Council for 
Harm onisat ion (ICH) guidelines and other applicable laws and regulat ions.
Docum entat ion of ERB approval o f the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s). All ICFs must be complian t with the ICH gui deline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance with the protocol and with
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 52
LY5731441)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Guidelines 
2)applicable ICH GCP Guidelines
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his o r her knowledge, the protocol accurately describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
The final report coordinat ing invest igator or designee will sign the clinical study report for this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
If thecoordinat inginvest igator is unable to fulfill this function, another invest igator will be 
chosen by Lilly to serve as the final report coordinating invest igator.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:
provi de instructi onal materi al to the study  sites, as appropriate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the CRFs, and study  procedures.
make peri odic visi ts to the study  site.
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collect ion.
condu ct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 53
LY573144The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the spon sor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.
The purpos e and use of subject personal informat ion collected will be provided in a written 
docum ent to the sub jectby the sponsor.
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the inves tigator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 54
LY573144Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic a bnorm ality and may  
be required in fo llow-up wi th subject s in consultation with Lilly or i ts desi gnee CRP.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear Antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPK Anti -smooth Muscle Antibody (or Anti-actin 
Antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 55
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol H8H -MC -LAIF Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volum e 
(mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 2 25
Lasmiditan and metabolite 
pharmacokinetics 2 52 104
Diphenhy dramine 
pharmacokinetics2 16 32
Total 180.5
Total for clinical purposes (rounded up to the nearest 10 mL) 190
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 56
LY573144Appendix 6. Protocol A mendment H8H-MC-LAIF(a)
Summary :A Phase I, Randomized, Subject -and 
Investigator -Blind, Placebo -Controlled, 4 -Period Cross -
Over Study  Assessing the Duration of Effect of 
Lasmiditan on Simulated Driving Performance in 
Healthy Volunteers
Overview
Protocol  H8H -MC-LAIF A Phase I, Rando mized, Subject -and Invest igator -Blind, Placebo -
Controlled, 4- Period Cross -Over Study  Assessing the Duration o f Effect of Lasmiditan on 
Simulated Driving Performance in Healt hy Vo lunteers has been amended.  The new prot ocol is 
indicated by  Amendment (a) and will be used to conduct the study  in place of any  preceding 
versio n of the protocol.
The overall change and rationale for the change made to this protocol are as fo llows:
Pharmacogen etic blood sampling was rem oved fro m study  inagreement withthe 
Sponsor’s Tailored Therapeut ics group.  The number of healt hy vo lunteers i s relatively 
small (<100) and a pharmacogen eticsample collecti on is unlikely  to enable invest igation 
of pharmacogen etic characteristics in migraine res ponse to l asmidi tan.
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 57
LY573144Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 58
LY5731442. Schedule of A ctivities
Screening Study Informed Consent
Medical History 
Subject Eligibility
Weight/Height (BMI)
Drug and Alcohol Screen (repeat alcohol screen prior to Driving 
Sim Training/Practice if performed at a separate visit)
Vital Signs
Physical Examination ( may be performed through Day -1)
Epworth Sleepiness Scale
Clinical Laboratory Tests
Twelve -Lead ECG
Temperature
Serum Pregnancy Test (females only)
CogScreen SDC Training/Screening
Driving Sim Training/Screening
Simulato r Sickness Questionnaire
Concomitant Medication assessment
Day -1 (Period 1) Admission to Clinic
Sample for Pharmacogenetic Analysis (prior to or on Day 1, 
Period 1)
Confirm Subject Eligibility
Drug and Alcohol Screen
Serum Pregnancy Test (females only)
Vital Signs
Directed Physical Examination (symptom driven)
CogScreen SDC Practice
Driving Sim Practice
Adverse Event Assessment
Concomitant Medication Assessment (monitor throughout study)
Day 1 (Periods 1 -4) Predose
Vital Signs
Directed Physical Examination (symptom driven)
Lasmiditan and Metabolites PK Sampling (predose)
Diphenhy dramine PK Sampling (predose)
+0.0 h Study Drug Administration (Dose 1)
+0.5 h Lasmiditan and Metabolites PK Sample a
+1.0 h
Lasmiditan and Metabolites PK Sample a
Breakfast
+1.5 h Lasmiditan and Metabolites PK Sample a
+2.0 h Vital Signs/Lasmiditan and Metabolites PK Sample a
+3.0 h Lasmiditan and Metabolites PK Sample a
+4.0 h
Vital Signs/Lasmiditan and Metabolites PK Sample a
Lunch
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 59
LY573144+6.0 h
Lasmiditan and Metabolites PK Sample a
Study Drug Administration (Dose 2)
+8.0 h
KSSb
Adverse Event Assessment b
CogScreen SDC Test b
Self-Perceived Questionnaire (safe to drive)
Lasmiditan and Metabolites PK Sample a
Diphenhy dramine PK Sample a
CVDA Drive
VAS (immediately after drive)
+10.0 h
Lasmiditan and Metabolites PK Sample a
Study Drug Administration (Dose 3)
+11.0 h Dinner
+12.0h
KSSb
Adverse Event Assessment b
CogScreen SDC Test b
Self-Perceived Questionnaire (safe to drive)
Lasmiditan and Metabolites PK Sample a
Diphenhy dramine PK Sample a
CVDA Drive
VAS (immediately after drive)
Day 2 (Periods 1 -4) +22 h Study Drug Administration (Dose 4)
+23 h Breakfast
+24 h
KSSb
Adverse Event Assessment b
CogScreen SDC Test b
Self-Perceived Questionnaire (safe to drive)
Lasmiditan and Metabolites PK Sample a
Diphenhy dramine PK Sample a`
CVDA Drive
VAS (immediately after drive)
+36 h Lasmiditan and Metabolites PK Sample a
Day 3 (Periods 1 -4) +48 h Lasmiditan and Metabolites PK Sample a
Discharge (Day 3, 
Period 4)Discharge from 
Clinical Unit
Vital Signs
Physical Examination
Clinical Laboratory Tests
Adverse Event Assessment
Concomitant Medication Assessment
Early  Discontinuation
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 60
LY573144Vital Signs
Physical Examination
Clinical Laboratory Tests
Twelve -Lead ECG
Urinaly sis Samples 
Serum Pregnancy Test (females only)
Adverse Event Assessment
Concomitant Medication assessment
Within 5 to 9 days 
after DischargeFollow -up
Vital Signs
Physical Examination
Clinical Laboratory Tests
Twelve -Lead ECG
Urinaly sis Samples
Serum Pregnancy Test (females only)
Adverse Event Assessment
Concomitant Medication Assessment
Abbreviations:  BMI = body mass index; CVDA = Country Vigilance -Divided Attention ; ECG = electrocardiogram; 
h = hours, KSS = Karolinska Sleepiness Scale; PK = pharmacokinetic ; SDC = Symbol Digit Coding ; VAS = 
Visual Analo g Scale .
aPharmacokinetic and pharmacodynamic sampling times are given as targets to be achieved within reasonable 
limits.  For PK sampling scheduled prior to driving assessments, the sampling window should be within -5 min to 
avoid conflict with driving assessment.  Otherwise, the standard PK sampli ng windows: predose: -15 minutes; 
>0 to 2 hours postdose: ±5 minutes; 2.5 to 6 hours postdose: ±10 minutes; 7 to 12 hours postdose: ±20 minutes; 
>12 hours postdose: ±30 minutes.  The samples will be taken as per schedule to maintain the blind but samples 
will be analyzed according to the randomi zation table .
bThis accompanying driving assessment procedure should occur within -30 minutes before the scheduled CVDA 
drive targeted for this sampling time
9.7. Genetics
A blood sam ple will be collected for phar macogenetic analysis as specified in the Schedule o f 
Activities (Section 2), where l ocal regulat ions allo w.
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
lasmiditan and to invest igate genet ic variants thought to play a role in migraine.  Assessment of 
variable res ponse may  include evaluati on of  AEs or differences in efficacy .
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the invest igative site personnel.
Samples will  be retained fo r a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and/or IRBs impose shorter time limits, for the study  at a f acilit y 
selected by  Lilly or i ts desi gnee.  This retention period enables use of new technologies , response 
H8H-MC-LAIF (a)Clinical Pharmacology Pro tocol Page 61
LY573144to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the development of lasmiditan or after lasmiditan is commercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequencing, geno me-wide associ ation studies, multiplex assays, and cand idate gene studies.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion. 
This sect ion is not applicable for this study .
Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol H8H -MC -LAIF Sampling Summary
PurposeBlood Volume per 
Sample (mL )Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 2 25
Lasmiditan and metabolite 
pharmacokinetics 2 52 104
Diphenhy dramine 
pharmacokinetics2 16 32
Pharmacogenetics 10 1 10
Total 190.5 180.5
Total for clinical purposes (rounded up to the nearest 10 mL) 200190